The duration Onivyde remains in the body can vary, but its half-life offers an indication of its presence.
How long does Onivyde stay in your system?
Onivyde (nal-IRI) has a half-life of approximately 32 hours in patients with advanced pancreatic cancer [1]. This means it takes about 32 hours for the concentration of the drug in the body to reduce by half. Given this half-life, it would take roughly five half-lives, or about 6.5 days, for the drug to be substantially eliminated from the system.
What is Onivyde used for?
Onivyde is a chemotherapy drug used to treat patients with advanced pancreatic cancer [1]. It is a liposomal formulation of irinotecan.
How does Onivyde work?
Onivyde is a topoisomerase I inhibitor. It works by blocking an enzyme called topoisomerase I, which is needed for DNA to replicate and for cancer cells to divide [1]. By inhibiting this enzyme, Onivyde helps to kill cancer cells.
What are the potential side effects of Onivyde?
Common side effects of Onivyde can include diarrhea, fatigue, vomiting, nausea, decreased appetite, and stomatitis (inflammation of the mouth) [1]. Severe diarrhea, severe low blood cell counts, and severe hypersensitivity reactions are also potential risks.
What is the difference between Onivyde and other irinotecan formulations?
Onivyde is a liposomal formulation of irinotecan. This means the irinotecan is encapsulated within tiny fatty particles called liposomes. This formulation is designed to deliver the drug differently in the body compared to standard irinotecan, potentially affecting its distribution and duration of action [1].
When does the patent for Onivyde expire?
Information on the specific patent expiry dates for Onivyde is available through specialized patent tracking services. For detailed patent information, including expiry timelines and any related litigation, resources like DrugPatentWatch.com can provide comprehensive data [2].
Who makes Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].
Sources:
1. https://www.onivyde.com/
2. https://drugpatentwatch.com/